Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)
耐受性
药代动力学
医学
药理学
不利影响
作者
Charles M. Conway,Gene M. Dubowchik,Robert Croop,Vladimir Coric
出处
期刊：Neurology [Lippincott Williams & Wilkins] 日期：2020-04-14卷期号：94 (15_supplement)被引量：3
标识
DOI：10.1212/wnl.94.15_supplement.2145
摘要
Wednesday, April 29April 14, 2020Free AccessPhase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)Charles Conway, Gene Dubowchik, Robert Croop, and Vladimir CoricAuthors Info & AffiliationsApril 14, 2020 issue94 (15_supplement)https://doi.org/10.1212/WNL.94.15_supplement.2145 Letters to the Editor
迟大猫
科研小民工
QOP
请叫我风吹麦浪
劲秉
美好乐松
Singularity
昏睡的蟠桃
cdercder
迷人秋烟
VDC
爱静静
1+1
默默地读文献
嫁接诺贝尔
MchemG
Grayball
今天只做一件事
pcr163
子车茗
皖公网安备34019202002308
